Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Washington
University of Virginia
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Fred Hutchinson Cancer Center
City of Hope Medical Center
University Health Network, Toronto
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Montefiore Medical Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
Mayo Clinic
Children's Hospital of Philadelphia
University of Miami
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
University of Southern California
Stanford University
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Institute of Hematology and Blood Transfusion, Czech Republic
Montefiore Medical Center
Montefiore Medical Center
University of Rochester
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institut Claudius Regaud
Ciusss de L'Est de l'Île de Montréal
Wake Forest University Health Sciences
Mayo Clinic
Stanford University
M.D. Anderson Cancer Center
Thomas Jefferson University
H. Lee Moffitt Cancer Center and Research Institute
Institut Claudius Regaud
University Hospital, Basel, Switzerland
Children's Hospital of Philadelphia